Ligand director Jason M. Aryeh proposes $385K share sale

The proposed-sale shares are listed as restricted stock acquired from Ligand Pharmaceuticals Inc. on June 5, 2026.

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. director Jason M. Aryeh reported a proposed sale of 1,209 common shares, with an aggregate market value of $385,185.47 and an approximate sale date of October 30, 2026. The sale details name Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are identified as restricted stock acquired from the issuer on June 5, 2026.

Key Figures

Common shares proposed for sale: 1,209 shares Aggregate market value: $385,185.47 Common shares outstanding: 19,935,609 shares

3 metrics

Common shares proposed for sale 1,209 shares Approximate sale date: October 30, 2026

Aggregate market value $385,185.47 Proposed sale

Common shares outstanding 19,935,609 shares Ligand Pharmaceuticals Inc.

Key Terms

Rule 144, Restricted Stock

2 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Restricted Stock"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares did Jason M. Aryeh propose to sell?

Jason M. Aryeh, a director of Ligand Pharmaceuticals Inc., reported a proposed sale of 1,209 common shares, with an aggregate market value of $385,185.47 and an approximate sale date of October 30, 2026. Morgan Stanley Smith Barney LLC Executive Financial Services is named in the sale details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 04:38 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:37 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001376960
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INCORPORATED
SEC File Number	001-33093
Address of Issuer	555 Heritage Drive, Suite 200 Jupiter FLORIDA 33458
Phone	(858) 550-7500
Name of Person for Whose Account the Securities are To Be Sold	JASON M ARYEH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1209	385185.47	19935609	10/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/05/2026	Restricted Stock	Issuer			1209	06/05/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jason Aryeh
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)